Prof. Severine Vermeire (University Hospital Leuven, Belgium) presented a 1-year, open-label ABX464 maintenance study conducted in 22 ulcerative colitis (UC) patients without treatment interruption after completion of the randomised, double-blind, placebo-controlled 8 weeks induction study . A total of 19 patients completed the 1-year maintenance study and showed good long-term safety and tolerability of 50 mg given orally over 52 weeks.
ABX464 is an oral drug candidate for UC, among other chronic inflammation disorders, with a novel mechanism of action based on the upregulation of a single microRNA (miRNA-124) with anti-inflammatory properties.
At month 12, an endoscopy to assess clinical remission status (the critical parameter for regulatory authorities) was performed in 16/19 UC patients. During treatment with ABX464, patients reduced their mean total Mayo Score from 8.7 to 1.9 (-78%), their endoscopic subscore from 2.3 to 0.25 (-89%), and th...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Immunonutrition during neoadjuvant oesophagogastric cancer therapy: no benefit Next Article
Global burden of digestive diseases reveals alarming trends »
Table of Contents: UEGW 2019
Upper GI Disorders
Irritable Bowel Syndrome
Inflammatory Bowel Diseases
Microbiome and Microbiota
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.